Patents by Inventor Leif Norskov-Lauritsen

Leif Norskov-Lauritsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Growth hormones with prolonged in-vivo efficacy
    Patent number: 8841249
    Abstract: The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.
    Type: Grant
    Filed: August 6, 2010
    Date of Patent: September 23, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Nils Langeland Johansen, Henrik Sune Andersen, Jens Buchardt, Leif Norskov-Lauritsen
  • Stable growth hormone compounds resistant to proteolytic degradation
    Patent number: 8513192
    Abstract: The present invention relates to stable growth hormone (GH) compounds, which through the introduction of cysteine residues have disulphide bridges, which make the compounds resistant to proteolytic degradation.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: August 20, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Ole Hvilsted Olsen, Jens Breinholt, Christine Bruun Schiødt, Helle Demuth, Leif Nørskov-Lauritsen, Peter Thygesen
  • Growth Hormones with Prolonged In-Vivo Efficacy
    Publication number: 20120172303
    Abstract: The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.
    Type: Application
    Filed: August 6, 2010
    Publication date: July 5, 2012
    Applicant: Novo Nordisk Health Care AG
    Inventors: Nils Langeland Johansen, Henrik Sune Andersen, Jens Buchardt, Carsten Behrens, Leif Norskov-Lauritsen, Jing Su
  • STABLE GROWTH HORMONE COMPOUNDS
    Publication number: 20110306548
    Abstract: The present invention relates to stable growth hormone (GH) compounds, which through the introduction of cysteine residues have disulphide bridges, which make the compounds resistant to proteolytic degradation.
    Type: Application
    Filed: January 22, 2010
    Publication date: December 15, 2011
    Applicant: Novo Nordisk Health Care AG
    Inventors: Ole Hvilsted Olsen, Jens Breinholt, Christine Bruun Schiødt, Helle Demuth, Leif Nørskov-Lauritsen, Peter Thygesen
  • Novel Prolactin Compounds
    Publication number: 20100292444
    Abstract: The present invention relates to prolactin analogues, which analogues have increased resistance to deamidation.
    Type: Application
    Filed: July 3, 2008
    Publication date: November 18, 2010
    Applicant: Novo Nordisk A/S
    Inventors: Jens Breinholt, Per Franklin Nielsen, Leif Christensen, Leif Nørskov-Lauritsen, Anders Swensson
  • Transglutaminase Variants with Improved Specificity
    Publication number: 20100099610
    Abstract: Variants of transglutaminase from Streptoverticillium ladakanum, which variants have improved selectivity for Gln-141 of human growth hormone are provided.
    Type: Application
    Filed: February 22, 2008
    Publication date: April 22, 2010
    Inventors: Sean Hu, Xao Zin, Wang Jianhua, Chihchuan Chang, Leif Nørskov-Lauritsen, Jing Su
  • Transglutaminase Variants with Improved Specificity
    Publication number: 20100087371
    Abstract: Variants of transglutaminase from Streptoverticillium ladakanum, which variants have improved selectivity for Gln-141 of human growth hormone are provided.
    Type: Application
    Filed: February 22, 2008
    Publication date: April 8, 2010
    Inventors: Sean Hu, Zhao Xin, Wang Jianhua, Chihchuan Chang, Leif Nørskov-Lauritsen, Jing Su
  • Dimeric Prolactin Receptor Ligands
    Publication number: 20100022456
    Abstract: The patent application relates to antagonistic dimers of prolactin molecules and their use in treating cancer.
    Type: Application
    Filed: December 20, 2007
    Publication date: January 28, 2010
    Applicant: Novo Nordisk A/S
    Inventors: Leif Christensen, Leif Norskov-Lauritsen, Lone Risegaard, Nils Billestrup, Svetlana Tarabykina
  • Peptides with High Affinity for the Prolactin Receptor
    Publication number: 20100022454
    Abstract: The present invention is concerned with peptides binding to the prolactin receptor, wherein said peptides have an improved binding via binding site 1 (BS1) to the prolactin receptor. In one embodiment, said improved binding is achieved by mutation of positions 61, 71 and 73.
    Type: Application
    Filed: October 3, 2007
    Publication date: January 28, 2010
    Applicant: Novo Nordisk A/S
    Inventors: Leif Norskov-Lauritsen, Leif Christensen
  • TRANSGLUTAMINASE VARIANTS WITH IMPROVED SPECIFICITY
    Publication number: 20090318349
    Abstract: Variants of transglutaminase from Streptoverticillium ladakanum, which variants have improved selectivity for Gln-141 of human growth hormone are provided.
    Type: Application
    Filed: August 17, 2007
    Publication date: December 24, 2009
    Applicant: Novo Nordisk Health Care AG
    Inventors: Zhixiang Hu, Xin Zhao, Jianhua Wang, Chih-Chuan Chang, Leif Norskov-Lauritsen
  • Transglutaminase Variants with Improved Specificity
    Publication number: 20090117640
    Abstract: Variants of transglutaminase from S. mobareanse, which variants have improved selectivity against Gln-40 og Gln-141 of human growth hormone are provided.
    Type: Application
    Filed: August 18, 2006
    Publication date: May 7, 2009
    Applicant: novo Nordisk Health Care AG
    Inventors: Leif Norskov-Lauritsen, Nils Langeland Johansen
  • Modified subtilisins and detergent, compositions containing same
    Patent number: 7189553
    Abstract: The present invention relates to enzymes produced by mutating the genes for a number of subtilisin proteases and expressing the mutated genes in suitable hosts are presented. The enzymes exhibit improved wash performance in comparison to their wild type parent enzymes. The enzymes are well-suited for use in detergent compositions.
    Type: Grant
    Filed: December 6, 2002
    Date of Patent: March 13, 2007
    Assignee: Novozymes A/S
    Inventors: Dorrit Aaslyng, Sven Branner, Sven Hastrup, Leif Norskov-Lauritsen, Ole Hvilsted Olsen, Merete Simonsen, Eric Castelijn, Maarten Robert Egmond, Johan Haverkamp, John David Marugg, Arnoldus Theodorus Anthonius Mooren
  • Modified subtilisins and detergent compositions containing same
    Patent number: 6632646
    Abstract: Enzymes produced by mutating the genes for a number of subtilisin proteases and expressing the mutated genes in suitable hosts are presented. The enzymes exhibit improved wash performance in comparison to their wild type parent enzymes. The enzymes are well-suited for use in detergent compositions.
    Type: Grant
    Filed: October 2, 2000
    Date of Patent: October 14, 2003
    Assignees: Novozymes A/S, Unilever PLC.
    Inventors: Dorrit Aaslyng, Sven Branner, Sven Hastrup, Leif Nørskov-Lauritsen, Ole Hvilsted Olsen, Merete Simonsen, Eric Casteleijn, Maarten Robert Egmond, Johan Haverkamp, John David Marugg, Arnoldus Theodorus Anthonius Mooren
  • Modified subtilisins and detergent, compositions containing same
    Publication number: 20030191039
    Abstract: The present invention relates to enzymes produced by mutating the genes for a number of subtilisin proteases and expressing the mutated genes in suitable hosts are presented. The enzymes exhibit improved wash performance in comparison to their wild type parent enzymes. The enzymes are well-suited for use in detergent compositions.
    Type: Application
    Filed: December 6, 2002
    Publication date: October 9, 2003
    Applicant: Novozymes A/S
    Inventors: Dorrit Aaslyng, Sven Branner, Sven Hastrup, Leif Norskov-Lauritsen, Ole Hvilsted, Merete Simonsen, Eric Casteleijn, Maarten Robert Egmond, Johan Haverkamp, John David Marugg, Arnoldus Theodorus Anthonius Mooren
  • Method of inhibiting liver glycogen phosphorylase with 2-alkylpyrrolidines
    Patent number: 6451836
    Abstract: The present invention relates to (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine and other substituted 2-methylpyrrolidines and their use for inhibiting liver glycogen phosphorylase.
    Type: Grant
    Filed: August 24, 1998
    Date of Patent: September 17, 2002
    Assignee: Novo Nordisk A/S
    Inventors: Karsten Lundgren, Palle Jakobsen, Marit Kristiansen, Leif Nørskov-Lauritsen, Lars Naerum
  • Modified subtilisins and detergent compositions containing same
    Patent number: 6197567
    Abstract: Enzymes produced by mutating the genes for a number of subtilisin proteases and expressing the mutated genes in suitable hosts are presented. The enzyme exhibit improved wash performance in comparison to their wild type parent enzymes. The enzymes are well-suited for use in detergent compositions.
    Type: Grant
    Filed: March 12, 1997
    Date of Patent: March 6, 2001
    Assignees: Novo Nordisk A/S, Unilever PLC
    Inventors: Dorrit Aaslyng, Sven Branner, Sven Hastrup, Leif Nørskov-Lauritsen, Ole Hvilsted Olsen, Merete Simonsen, Eric Casteleijn, Maarten Robert Egmond, Johan Haverkamp, John David Marugg, Arnoldus Theodorus Anthonius Mooren